Biotech

All Articles

AstraZeneca posts data on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early consider the functionality of its own internal antibody...

iTeos- GSK's TIGIT superstar presents relevant improvement

.After revealing a period 3 launch based upon beneficial midstage outcomes, iTeos and also GSK are a...

More collaborative FDA can easily speed up rare disease R&ampD: record

.The FDA must be more open and collaborative to unleash a rise in approvals of unusual health condit...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bicara T...

Atea's COVID antiviral falls short to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has fallen short another COVID-19 test, but the biotech still keeps...

Neurocrine's offer to spare schizophrenia prospect neglects

.Neurocrine Biosciences' schizophrenia plan pivot has failed. The biotech was actually unable to rep...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has brought in a late entry to the radioligand gathering, paying out one hundred million eur...

F 2G raises $100M for second attempt to get brand-new antifungal to market

.After F2G's initial attempt to obtain a brand-new course of antifungal to market was thwarted by th...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 plans amid profits tensions

.Moderna has vowed to cut R&ampD spending by $1.1 billion by 2027. The decision to retract the spend...

Sanofi's $80M bank on Pivot dystrophy medication finishes in phase 3 fail

.Merely 4 months after Sanofi bet $80 thousand in ahead of time cash money on Key Therapies' losmapi...